Kazia Licenses Ovarian Cancer Drug to Swedish Pharmaceutical Company
Australian oncology-focused company, Kazia Therapeutics has just announced a license agreement with Swedish speciality pharmaceutical company Oasmia Pharmaceutical for its ovarian cancer drug Cantrixil.
Read More